Denosumab for Treatment of a Recurrent Cervical Giant-Cell Tumor.
10.4184/asj.2016.10.3.553
- Author:
Daisuke KAJIWARA
1
;
Hiroto KAMODA
;
Tsukasa YONEMOTO
;
Shintaro IWATA
;
Takeshi ISHII
;
Toshinori TSUKANISHI
;
Seiji OHTORI
;
Masashi YAMAZAKI
;
Akihiko OKAWA
Author Information
1. Department of Orthopedic Surgery, Chiba Cancer Center, Chiba, Japan. kamodahiroto@gmail.com
- Publication Type:Case Report
- Keywords:
Cervical vertebrae;
Giant cell tumor of bone;
Recurrence;
Denosumab
- MeSH:
Adult;
Cervical Vertebrae;
Denosumab*;
Female;
Follow-Up Studies;
Giant Cell Tumor of Bone;
Giant Cell Tumors;
Humans;
Male;
Neck;
Recurrence;
Shoulder Pain;
Spine
- From:Asian Spine Journal
2016;10(3):553-557
- CountryRepublic of Korea
- Language:English
-
Abstract:
A 43-year-old male patient with C5 giant cell tumor (GCT) underwent tumor resection and anterior bone fusion of C4-C6. The tumor recurred locally 9 months after surgery with the patient complaining of neck and shoulder pain similar to his preoperative symptoms. Denosumab was administered and his pain disappeared after a two-month administration, with a sclerotic rim formation seen at the tumor site on computed tomography. He has been followed for 18 months with no evidence of tumor recurrence. Complete resection is generally recommended, but is not easy for many patients with cervical GCT because of the existence of neurovascular structures. Some patients suffer from recurrence and treatment becomes more difficult. As such, denosumab may be an efficacious option for treatment of recurrent GCT of the cervical spine, although long-term follow-up is required to monitor for presence or absence of recurrence.
